This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pelloski, C. E. Articles by Aldape, K. D. Search for Related Content PubMed PubMed Citation Articles by Pelloski, C. E. Articles by Aldape, K. D.

YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma

Authors' Affiliations: Departments of ¹ Radiation Oncology, ² Neuro-Oncology, and ³ Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, and ⁴ Department of Pathology and Laboratory Medicine, Mayo Clinic and Foundation, Rochester, Minnesota

Requests for reprints: Kenneth D. Aldape, Department of Pathology, Box 85, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-7935; Fax: 713-745-1105; E-mail: kaldape{at}mdanderson.org.

Purpose: YKL-40 is a secreted protein that has been reported to be overexpressed in epithelial cancers and gliomas, although its function is unknown. Previous data in a smaller sample set suggested that YKL-40 was a marker associated with a poorer clinical outcome and a genetically defined subgroup of glioblastoma. Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response.

Experimental Design: Patients (n = 147) with subtotal resections were studied for imaging-assessed changes in tumor size in serial studies following radiation therapy. An additional set (n = 140) of glioblastoma patients who underwent a gross-total resection was tested to validate the survival association and extend them to patients with minimal residual disease.

Results: In the subtotal resection group, higher YKL-40 expression was significantly associated with poorer radiation response, shorter time to progression and shorter overall survival. The association of higher YKL-40 expression with poorer survival was validated in the gross-total resection group. In multivariate analysis with both groups combined (n = 287), YKL-40 was an independent predictor of survival after adjusting for patient age, performance status, and extent of resection. YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization. YKL-40 was significantly associated with 10q loss.

Conclusions: The findings implicate YKL-40 as an important marker of therapeutic response and genetic subtype in glioblastomas and suggest that it may play an oncogenic role in these tumors.

Key Words: Glioma • immunohistochemistry • prognostic marker

This article has been cited by other articles:

				H. Colman and K. Aldape Molecular Predictors in Glioblastoma: Toward Personalized Therapy Arch Neurol, July 1, 2008; 65(7): 877 - 883. [Abstract] [Full Text] [PDF]

				M. Shirahata, K. Iwao-Koizumi, S. Saito, N. Ueno, M. Oda, N. Hashimoto, J. A. Takahashi, and K. Kato Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis Clin. Cancer Res., December 15, 2007; 13(24): 7341 - 7356. [Abstract] [Full Text] [PDF]

				H. Aoki, T. Yokoyama, K. Fujiwara, A. M. Tari, R. Sawaya, D. Suki, K. R. Hess, K. D. Aldape, S. Kondo, R. Kumar, et al. Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma Clin. Cancer Res., November 15, 2007; 13(22): 6603 - 6609. [Abstract] [Full Text] [PDF]

				C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W.K. A. Yung, H. Colman, et al. Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma J. Clin. Oncol., June 1, 2007; 25(16): 2288 - 2294. [Abstract] [Full Text] [PDF]

				A. Hormigo, B. Gu, S. Karimi, E. Riedel, K. S. Panageas, M. A. Edgar, M. K. Tanwar, J. S. Rao, M. Fleisher, L. M. DeAngelis, et al. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. Clin. Cancer Res., October 1, 2006; 12(19): 5698 - 5704. [Abstract] [Full Text] [PDF]

				C.-L. Tso, P. Shintaku, J. Chen, Q. Liu, J. Liu, Z. Chen, K. Yoshimoto, P. S. Mischel, T. F. Cloughesy, L. M. Liau, et al. Primary Glioblastomas Express Mesenchymal Stem-Like Properties Mol. Cancer Res., September 1, 2006; 4(9): 607 - 619. [Abstract] [Full Text] [PDF]

				C. E. Pelloski, E Lin, L. Zhang, W.K. A. Yung, H. Colman, J.-L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, et al. Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma. Clin. Cancer Res., July 1, 2006; 12(13): 3935 - 3941. [Abstract] [Full Text] [PDF]

				H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804. [Abstract] [Full Text] [PDF]

				J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF]